Research
Hormonal
Adipose tissue acts as an endocrine organ in obesity, secreting inflammatory cytokines (like TNF-alpha) and adipokines (like RBP4) that induce insulin resistance in the liver and muscle.
Weight loss reduces the mass of adipose tissue, thereby reducing the secretion of inflammatory cytokines and adipokines that drive insulin resistance. This improves the body's ability to manage blood sugar and reduces fat accumulation in the liver.
GoodSupportsHIGH confidence
Adipocytes excrete a number of bioactive peptides that are collectively called 'adipokines'... In obese states, adipocytes also excrete inflammatory cytokines... It has been found that TNF-alpha is over expressed in obese people... RBP4 works partly by blocking the action of insulin in muscle and liver.
Why this rating
Supported by multiple citations in the review.
Source
Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment
T.C.M.A. Schreuder et al. · World Journal of Gastroenterology · 2008
DOI 10.3748/wjg.14.2474
narrative_reviewCited 190×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance drives hepatic steatosis by disrupting normal insulin signaling, leading to unchecked de novo lipogenesis and increased free fatty acid flux from visceral adipose tissue.Good
- Progression from simple steatosis to steatohepatitis (NASH) is driven by a 'second hit' involving oxidative stress, inflammation, and mitochondrial dysfunction, often triggered by excess free fatty acids.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →